8-K: Matinas BioPharma Announces Positive Outcomes in Expanded Access Program for MAT2203

Matinas BioPharma reports positive results from its compassionate use program for MAT2203, showing reversal of renal impairment and clinical improvement in patients with invasive fungal infections.

Summary

• Matinas BioPharma provided an update on its Compassionate/Expanded Use Access Program for MAT2203, an oral formulation of amphotericin B.
• The program enrolled 19 patients with serious fungal infections, many of whom had limited treatment options.
• 15 patients had available follow-up data, with 12 showing either complete clinical resolution or objective improvement in infection markers.
• All 5 patients who completed their full course of treatment experienced complete clinical resolution with no relapses.
• Patients who experienced renal toxicity from AmBisome saw their renal function return to baseline after switching to MAT2203.
• The infections treated included Aspergillus, Mucorales, Candidiasis, Fusarium, and suspected Coccidioides, affecting various body sites.
• Most patients had previously received AmBisome but developed nephrotoxicity or had failed azole therapy.

Sentiment

Score: 8

Explanation: The document presents very positive clinical results for MAT2203, particularly the reversal of renal toxicity and high rates of clinical improvement. While there are some patient dropouts and a death, these are attributed to underlying conditions and do not detract from the overall positive sentiment. The company's forward-looking statements are also optimistic, indicating a high probability of success in the upcoming Phase 3 trial.

Positives

• MAT2203 demonstrated a positive clinical impact in patients with limited treatment options for serious fungal infections.
• The oral formulation of MAT2203 was well-tolerated by patients.
• The study showed a reversal of renal impairment in patients who switched from AmBisome to MAT2203.
• MAT2203 has the potential to be a significant improvement over current treatments for invasive fungal infections.
• The results suggest a high clinical probability of success for MAT2203 in a well-controlled clinical trial.

Negatives

• 5 out of 15 patients were unable to complete their full course of treatment.
• 2 patients transitioned to palliative care due to progression of their underlying malignant disease.
• 1 patient discontinued therapy due to underlying GI issues.
• 1 patient passed away due to progression of their underlying disease, although they had previously shown clinical improvement.
• 1 patient discontinued treatment due to GI issues, despite improvement in their fungal infection.

Risks

• The company's ability to obtain additional capital to meet its liquidity needs is a risk.
• There are uncertainties inherent in clinical testing and obtaining regulatory approvals.
• The company faces competition and changes in the regulatory landscape.
• The company's product candidates are all in a development stage and are not available for sale or use.
• The company's ability to protect its intellectual property is a risk.

Future Outlook

Matinas BioPharma plans to advance MAT2203 into Phase 3 development with the ORALTO registration trial, aiming to validate the positive results in a well-controlled clinical setting. The company believes the clinical probability of success is quite high and that MAT2203 could become the treatment of choice for invasive fungal infections if approved.

Management Comments

• Dr. Marisa Miceli stated that MAT2203 may be particularly promising for the treatment of invasive fungal infections in patients with limited options.
• Theresa Matkovits, PhD, expressed excitement about the consistent positive clinical impact of MAT2203 and looks forward to advancing it into Phase 3 development.

Industry Context

The announcement highlights the potential of MAT2203 to address the unmet need for effective and safe treatments for invasive fungal infections, particularly in patients who have developed resistance or intolerance to existing therapies like AmBisome and azoles. The development of an oral formulation of amphotericin B could be a significant advancement in the field.

Comparison to Industry Standards

• AmBisome, a liposomal formulation of amphotericin B, is a standard treatment for invasive fungal infections but is known for its renal toxicity, which MAT2203 aims to mitigate.
• Azole antifungals are another class of drugs used for these infections, but resistance is a growing concern, making MAT2203 a potential alternative for patients who have failed azole therapy.
• The successful Phase 2 EnACT study of MAT2203 in HIV patients with cryptococcal meningitis provides a benchmark for its efficacy, and the planned Phase 3 ORALTO trial will further validate its potential against standard of care treatments.

Stakeholder Impact

• Shareholders may view the positive clinical results as a positive development for the company.
• Patients with invasive fungal infections may benefit from the development of MAT2203.
• Healthcare providers may have a new treatment option for patients with limited alternatives.

Next Steps

• Matinas BioPharma plans to advance MAT2203 into a Phase 3 registration trial (ORALTO).
• The company will continue to monitor patients in the Compassionate/Expanded Use Access Program.

Key Dates

Keywords

MAT2203, fungal infections, amphotericin B, liposomal amphotericin B, renal toxicity, compassionate use, clinical trial, LNC, oral drug delivery, aspergillosis, mucormycosis, candidiasis